Stifel Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $98
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $98.
Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $98.